EnKang Pharmaceuticals

Enkang Pharmaceuticals is a clinical-stage biotechnology company headquartered in Guangzhou, China, specializing in the development of first-in-class anti-cancer therapeutics. The company's core technology centers on DNA Replication Initiation Protein (DRIP) inhibitors, a novel class of drugs designed to selectively target the replication machinery of cancer cells. Its lead candidate, EN002, is a small molecule MCM7 inhibitor currently undergoing Phase 1/2 clinical trials for the treatment of actinic keratosis and basal cell carcinoma. Enkang's pipeline also includes EK4-106, a topical vaginal gel for cervical precancerous lesions, and a cisplatin liposome inhaler for small cell lung cancer. Founded by prominent academics from the Hong Kong University of Science and Technology, the company maintains research facilities in Guangzhou, Hong Kong, and Macau to advance its portfolio of targeted, low-toxicity oncology treatments.